Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hapatitis C

World Journal of Gastroenterology

Volumn 12, Issue 34, 2006, Pages 5554-5556

  Gupta, Rajesh ^a   Ramakrishna, C H ^a   Lakhtakia, Sandeep ^a   Tandan, Manu ^a   Banerjee, Rupa ^a   Reddy, D Nageshwar ^a  

^a ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

Author keywords

Chronic hepatitis C; Peginterferon alpha 2b; Ribvirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; BODY WEIGHT; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; LOW DRUG DOSE; MALE; THROMBOCYTOPENIA; URETHRA DISEASE; WEAKNESS;

EID: 33749409746     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i34.5554     Document Type: Article

References (16)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47
2. Das BR, Kundu B, Khandapkar R, Sahni S. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002; 45: 323-328
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52
4. SSeeff LB, Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46
5. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881
6. Poynard T, Marcellin P, Lee SS, Niederau. C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998; 352: 1426-1432
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492
8. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002; 36: S3-20
9. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403
10. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672
11. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
13. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
14. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999
15. Fan WM, Zhu WF, Yin LM, Wei L, Xu XY, Zhuang H. Prospective study in 142 cases of hepatitis C virus infection. World J Gastroenterol 2004; 10: 2867-2869
16. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-244